Trichinella spiralis: Monoclonal antibody against the muscular larvae for the detection of circulating and fecal antigens in experimentally infected rats

Zumaquero-Ríos, José-Lino; García-Juarez, Jazmín; de-la-Rosa-Arana, Jorge-Luis; Marcet, Ricardo; Sarracent-Pérez, Jorge

doi:10.1016/j.exppara.2012.09.016

Cited by 17 publications

(10 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antigen detection may provide a tool for the serological monitoring of anti-parasitic therapies and for the study of the interactions between Trichinella and its hosts [40], [48]. Various methods have been developed to detect circulating antigens (CAg) of Trichinella , including counter-immunoelectrophoresis, immunoradiometric assays, Dot blots, and ELISAs [40], [48].…”

Section: Antigen and Detection Methodsmentioning

confidence: 99%

Serological tools for detection of Trichinella infection in animals and humans

Yang¹,

Cai

Tong

et al. 2016

One Health

View full text Add to dashboard Cite

Trichinellosis is a serious foodborne zoonotic disease. It is an important threat to public health in both developing and developed countries. Human infections are strongly associated with consuming undercooked meat containing infective Trichinella larvae. The development of serological tools has enabled seroepidemiological studies and contributed to our knowledge on the importance of this parasite. Serological tests can also help the diagnosis of parasite infections in humans and the surveillance of animals. Generally speaking, serological techniques include detection methods for specific antibodies and for circulating parasite antigens in the serum or tissue fluids. Here, we present a comprehensive review of various methods used in the detection of antibodies against Trichinella and circulating parasite antigens in animals and humans.

show abstract

Section: Antigen and Detection Methodsmentioning

confidence: 99%

Serological tools for detection of Trichinella infection in animals and humans

Yang¹,

Cai

Tong

et al. 2016

One Health

View full text Add to dashboard Cite

show abstract

“…The available diagnostic techniques have relatively low sensitivities and specificities which necessitates replacement with new diagnostic tools with high sensitivity to detect infections agents in individuals and to assess chemotherapeutic efficacy. Since after the discovery of mAbs, they have been used in diagnosis of many important parasitic helminths (Zumaquero-Ríos et al, 2012) and protozoan (Srinivasan et al, 2014) diseases (Plasmodium spp, dirofilariosis, trichinellosis, trypanosomosis, leishmanosis, anaplasmosis, etc), bacterial (Tamborrini et al, 2010) diseases (anthrax, brucellosis, paratuberculosis, leptospirosis, listeriosis, clostridial infections, mycoplasmosis, etc), fungal diseases (zygomycosis, cryptococcosis, histoplasmosis, etc) viral diseases (foot-and-mouth disease, infectious bovine rhinotracheitis, bovine viral diarrhoea, blue tongue, classical swine fever and rabies, etc). Similarly mAbs are used to evaluate emerging viral diseases like Hendra (Xu et al, 2013) and Nipah viral infections.…”

Section: Monoclonal Antibodies In Diagnosis Of Infectious Diseasesmentioning

confidence: 99%

“…Interestingly, mAbs application in competitive ELISA has come to the forefront as a technique to detect the presence of anti-organism antibody. Since after its inception, the prominent advantage of its specificity of a single clone preparation allows the use of even crude antigen preparation for its production (Zumaquero-Ríos et al, 2012). Advancement in biotechnology has contributed in the large scale production of mAbs which forms an integral part of many diagnostic techniques.…”

Section: Introductionmentioning

confidence: 99%

Monoclonal antibodies in immunodiagnostic assays: a review of recent applications

Mahmuda¹,

Bande²,

Abdulhaleem³

et al. 2017

Sokoto J. Vet. Sc.

View full text Add to dashboard Cite

Monoclonal antibodies (mAbs) have proven to be effective biological reagents in the immunodiagnostic assays. This is due to their binding accuracy to many pathogens, thus, making them valuable research tools. Since the discovery of hybridoma technology by Kohler and Milstein, the use of monoclonal antibodies produced by the hybrid cells have been employed in diagnosis of several diseases. Monoclonal antibody production has several procedures with considerable variations, but the principles remain the same. Improvements in the field of cell culture technology have led to the production of improved qualities of monoclonal antibodies. In general, these antibodies are important biomedical reagents used in research, especially in the field of laboratory diagnostics for a number of different types of diseases in humans and animals. Some of the areas where application of monoclonal antibodies triumph are herein discussed. This review is aimed to assess various diagnostic assay techniques where monoclonal antibodies are applied in order to provide a first-hand information, especially for beginners in monoclonal antibody production, characterisation, evaluation and /or its applications in research and diagnosis.

show abstract

“…To determine whether blocking the C9-binding domain of Ts -Pmy would inhibit the protection employed by Ts -Pmy against complement attack and therefore enhance the complement-mediated killing of T. spiralis parasites, we incubated T. spiralis NBL with mAb 9G3 before adding fresh human serum as a source of complement. NBL were chosen as a target for the complement killing assay because the NBL stage is the stage that migrates through the blood and lymphatic circulation to muscular tissue and is exposed directly to the host immune system, thus, this stage should develop sophisticated abilities to evade complement attack, such as complement-binding Ts -Pmy [18], as a survival strategy [5]. Blocking Ts -Pmy on the surface of T. spiralis NBL by incubating live NBL with mAb 9G3 resulted in significantly enhanced complement-mediated killing of NBL in the presence of fresh human serum in vitro , suggesting that blocking the C9-binding domain of Ts -Pmy with mAb 9G3 efficiently inhibits the function of Ts -Pmy that protects the parasite from being attacked by host complement.…”

Section: Discussionmentioning

confidence: 99%

“…Due to the predominantly zoonotic importance of infection, new regulations for meat inspection and efficient quality control measures have been studied and enacted in recent years [3]. In addition, the identification of potential vaccine candidates, proteins and protective antibodies has been used as an important strategy for the control of T. spiralis infection [4,5]. …”

Section: Introductionmentioning

confidence: 99%

Monoclonal antibody targeting complement C9 binding domain of Trichinella spiralis paramyosin impairs the viability of Trichinella infective larvae in the presence of complement

et al. 2014

View full text Add to dashboard Cite

BackgroundTrichinella spiralis expresses paramyosin (Ts-Pmy) not only as a structural protein but also as an immunomodulator that inhibits host complement as a survival strategy. Previous studies demonstrated that Ts-Pmy bound to complement components C8 and C9 and inhibited the polymerization of C9 during the formation of the membrane attack complex (MAC). The C9 binding domain of Ts-Pmy was identified within 14 amino acid residues at the C-terminus of Ts-Pmy. The production of a monoclonal antibody that specifically targets the C9 binding site is necessary for further studies of Ts-Pmy function and may be used as a therapeutic agent for T. spiralis infection.MethodsIn this study, a monoclonal antibody against the complement C9 binding domain of Ts-Pmy (mAb 9G3) was produced using hybridoma technology. The binding activity of the mAb produced for recombinant or native Ts-Pmy and the blockade of Ts-Pmy binding to C9 by the mAb were assessed by Western blot analysis. The effect of the mAb on the viability of T. spiralis was observed by co-incubation of T. spiralis with mAb 9G3 in the presence of complement in vitro and by passive transfer of the mAb into naive mice following T. spiralis larval challenge.ResultsmAb 9G3 was successfully produced against the C9 binding domain of Ts-Pmy and bound specifically not only to recombinant Ts-Pmy but also to native Ts-Pmy expressed in different stages of T. spiralis, including adult worms, newborn larvae and muscle larvae. The binding of mAb 9G3 to Ts-Pmy efficiently blocked the binding of Ts-Pmy to human complement C9, resulting in a significant increase in the complement-mediated killing of newborn larvae in vitro and reduced infectivity of T. spiralis larvae in mice passively transferred with the mAb.ConclusionsmAb 9G3 is a specific antibody that binds to the C9 binding domain of Ts-Pmy and interferes with Ts-Pmy’s complement-binding activity. Therefore, this mAb is a protective antibody that has potential as a preventive and therapeutic agent for T. spiralis infection.

show abstract

Trichinella spiralis: Monoclonal antibody against the muscular larvae for the detection of circulating and fecal antigens in experimentally infected rats

Cited by 17 publications

References 27 publications

Serological tools for detection of Trichinella infection in animals and humans

Serological tools for detection of Trichinella infection in animals and humans

Monoclonal antibodies in immunodiagnostic assays: a review of recent applications

Monoclonal antibody targeting complement C9 binding domain of Trichinella spiralis paramyosin impairs the viability of Trichinella infective larvae in the presence of complement

Contact Info

Product

Resources

About